Comprehensive molecular profiling may provide a clearer picture of how high-grade serous ovarian cancer differs between patients and how the disease changes after exposure to chemotherapy.
In a study published in Nature Communications, researchers from the TumorProfiler Consortium evaluated whether an extensive combination of molecular and functional tests could be completed quickly enough to support treatment planning. Their findings suggest that detailed tumor profiling can identify patient-specific therapeutic opportunities while revealing a marked increase in cancer cell heterogeneity following chemotherapy.
The study, led by Francis Jacob, Viola Heinzelmann-Schwarz, and colleagues, was published on July 13, 2026.
Looking Beyond a Single Tumor Sample
High-grade serous ovarian cancer is increasingly understood not as one uniform disease, but as a collection of biologically diverse tumors that may respond differently to treatment.
To capture this complexity, the researchers examined several types of patient material, including blood, bulk tumor tissue, individual tumor cells, and malignant ascites, the fluid that can accumulate in the abdomen of patients with ovarian cancer.
The samples were analyzed using as many as 11 different technologies. These included assessments of DNA, RNA, proteins, cellular characteristics, and functional drug responses.
By bringing these layers of information together, the investigators sought to develop a more complete biological profile for each patient rather than relying on a single mutation, biomarker, or tissue sample.
Eleven Technologies Within Four Weeks
A major challenge in comprehensive tumor profiling is whether results can be produced quickly enough to remain clinically relevant.
In this study, the multimodal analysis was completed within a four-week turnaround time. This demonstrated that highly detailed profiling across several biological levels may be feasible within a timeframe that could inform treatment discussions.
The approach extended beyond conventional genomic testing. Researchers also evaluated gene expression, protein patterns, single-cell characteristics, and how living tumor cells responded to different treatments outside the body.
Together, these methods provided a more detailed view of both the molecular structure of the cancer and its functional behavior.
Treatment Recommendations Changed for 76% of Patients
The profiling results had a substantial effect on the hypothetical treatment recommendations developed for the study.
After the molecular and functional information was reviewed, treatment recommendations were altered for 76% of patients. This finding suggests that conventional clinical information alone may not identify all potentially relevant therapeutic options.
The researchers also reported that multi-omics-guided maintenance treatment was associated with prolonged overall survival in a subset of patients.
However, the findings should be interpreted carefully. The treatment recommendations were hypothetical, and the reported survival association does not establish that molecularly guided treatment directly caused the improved outcomes. Prospective clinical studies will be needed to determine whether this approach can consistently benefit patients.
Ascites and Solid Tumors Tell Different Stories
The study also revealed important differences depending on where tumor cells were collected.
Cancer cells obtained from malignant ascites showed distinct cellular and molecular characteristics compared with cells taken from solid tumor tissue. This indicates that a tissue biopsy may not always capture the full biological diversity of ovarian cancer within an individual patient.
The findings also raise questions about which sample should be used when selecting treatment. A therapy chosen according to the profile of the solid tumor may not have the same activity against cancer cells circulating or surviving within ascitic fluid.
Analyzing multiple tumor compartments could therefore provide a broader understanding of the disease and its potential vulnerabilities.
Drug Responses Were Unique to Each Patient
Functional testing further demonstrated that tumor cells from different patients did not respond uniformly to the same treatments.
The researchers observed distinct ex vivo drug-response patterns for individual patients. In these experiments, living cancer cells were exposed to different therapies outside the body to determine which drugs produced a measurable response.
These patient-specific results reflect the biological diversity of high-grade serous ovarian cancer and support the principle that tumors with similar clinical diagnoses may still have very different treatment sensitivities.
Functional drug testing could potentially complement genomic profiling by showing not only which molecular alterations are present, but also how the cancer cells respond when directly exposed to treatment.
Chemotherapy May Increase Tumor Heterogeneity
One of the study’s most notable findings was the increase in cancer cell heterogeneity observed following chemotherapy exposure.
After treatment, cancer cell populations became more diverse at the molecular and cellular levels. This increased complexity coincided with changes in genomic signatures among patients whose tumors showed whole-genome amplification.
The findings suggest that chemotherapy may do more than reduce the number of cancer cells. It may also reshape the remaining tumor population by creating conditions in which certain cellular groups survive, expand, or develop different molecular characteristics.
As a result, a tumor analyzed after chemotherapy may be considerably different from the disease present before treatment began.
Could Molecular Guidance Come Earlier?
Chemotherapy remains the primary standard treatment for women with high-grade serous ovarian cancer. However, the study raises the possibility that waiting until after chemotherapy to introduce molecularly selected therapies may limit their potential value.
If chemotherapy increases tumor heterogeneity, applying a targeted strategy only after treatment could mean confronting a more complex and biologically diverse disease.
The authors therefore suggest that molecularly guided treatments should be investigated as adjuvant therapies before chemotherapy in future clinical studies. Testing this approach prospectively will be essential to determine whether earlier molecular guidance can improve treatment effectiveness or delay the emergence of resistant tumor populations.
Building a More Complete Picture of Ovarian Cancer
The study provides a detailed tumor-profiling resource that connects genomic, transcriptomic, proteomic, single-cell, and functional information across different patient samples.
Its findings demonstrate that comprehensive profiling can be completed within four weeks, can substantially alter hypothetical treatment recommendations, and can uncover biological differences that may be missed through conventional testing alone.
The results also illustrate how ovarian cancer can evolve under treatment pressure. By showing that chemotherapy is associated with increased tumor heterogeneity, the research highlights the importance of considering when tumor profiling is performed—not only which technologies are used.
Further clinical trials will be required before this strategy can be incorporated into routine care. Nevertheless, the work offers a framework for studying how individualized molecular information could be used earlier and more effectively in the treatment of high-grade serous ovarian cancer.
Study Information
The research was conducted by Francis Jacob, Rebekka Wegmann, Joanna Ficek-Pascual, Ulrike Lischetti, Jack Kuipers, Stéphane Chevrier, Michael Prummer, Nora C. Toussaint, Ilaria Alborelli, Ricardo Coelho, and colleagues from the TumorProfiler Consortium.
The study, titled “A Tumor Profiling Resource for Ovarian Cancer: Insights Into Chemotherapy-Driven Heterogeneity and Personalized Treatment Strategy,” was published in Nature Communications.
The Swiss Tumor Profiler Study was jointly funded through a public-private partnership involving F. Hoffmann-La Roche Ltd., ETH Zurich, the University of Zurich, University Hospital Zurich, and University Hospital Basel, with additional support from several research grants and foundations.
At the time of publication, the journal noted that the available manuscript was an unedited version released to provide early access to the findings and would undergo further editorial processing.
Written by Nare Hovhannisyan, MD
Discover more articles like this on OncoDaily.